

Paul Cockwell

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8126595/publications.pdf>

Version: 2024-02-01

148
papers

7,616
citations

53660

45
h-index

62479

80
g-index

151
all docs

151
docs citations

151
times ranked

8047
citing authors

#	ARTICLE	IF	CITATIONS
1	Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. <i>Blood</i> , 2012, 120, 4292-4295.	0.6	447
2	The global burden of chronic kidney disease. <i>Lancet</i> , The, 2020, 395, 662-664.	6.3	342
3	The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. <i>Nature Reviews Nephrology</i> , 2019, 15, 45-59.	4.1	330
4	Quantitative Assessment of Serum and Urinary Polyclonal Free Light Chains in Patients with Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1684-1690.	2.2	297
5	Efficient Removal of Immunoglobulin Free Light Chains by Hemodialysis for Multiple Myeloma: In Vitro and In Vivo Studies. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 886-895.	3.0	245
6	Treatment of Acute Renal Failure Secondary to Multiple Myeloma with Chemotherapy and Extended High Cut-Off Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 745-754.	2.2	220
7	Macrophages and progressive tubulointerstitial disease. <i>Kidney International</i> , 2005, 68, 437-455.	2.6	189
8	Early Reduction of Serum-Free Light Chains Associates with Renal Recovery in Myeloma Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1129-1136.	3.0	188
9	Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure. <i>BMC Nephrology</i> , 2008, 9, 11.	0.8	159
10	Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis 1. <i>Kidney International</i> , 2001, 59, 1729-1738.	2.6	148
11	Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. <i>Circulation</i> , 2018, 138, 1505-1514.	1.6	145
12	The role of capillary density, macrophage infiltration and interstitial scarring in the pathogenesis of human chronic kidney disease. <i>Kidney International</i> , 2008, 74, 495-504.	2.6	137
13	Meta-Analysis of Calcineurin-Inhibitor-Sparing Regimens in Kidney Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 2107-2118.	3.0	127
14	Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. <i>BMJ: British Medical Journal</i> , 2003, 326, 789-789.	2.4	125
15	Interleukin-8: A pathogenetic role in antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. <i>Kidney International</i> , 1999, 55, 852-863.	2.6	124
16	Increased Expression of Mineralocorticoid Effector Mechanisms in Kidney Biopsies of Patients With Heavy Proteinuria. <i>Circulation</i> , 2005, 112, 1435-1443.	1.6	121
17	Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. <i>Kidney International</i> , 2008, 74, 1343-1353.	2.6	115
18	Fractalkine expression in human renal inflammation. <i>Journal of Pathology</i> , 2002, 196, 85-90.	2.1	114

#	ARTICLE	IF	CITATIONS
19	Immunoglobulin free light chain levels and recovery from myeloma kidney on treatment with chemotherapy and high cut-off haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3823-3828.	0.4	113
20	Association between periodontitis and mortality in stages 3â€“5 chronic kidney disease: <scp>NHANES III</scp> and linked mortality study. <i>Journal of Clinical Periodontology</i> , 2016, 43, 104-113.	2.3	110
21	The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review. <i>PLoS ONE</i> , 2020, 15, e0230512.	1.1	96
22	The biology of immunoglobulin free light chains and kidney injury. <i>Kidney International</i> , 2011, 79, 1289-1301.	2.6	94
23	European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): A randomised control trial. <i>Trials</i> , 2008, 9, 55.	0.7	90
24	Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors. <i>Hypertension</i> , 2016, 67, 368-377.	1.3	85
25	Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, gfv346.	0.4	81
26	Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: A systematic review. <i>PLoS ONE</i> , 2017, 12, e0179733.	1.1	80
27	High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial. <i>Lancet Haematology</i> , 2019, 6, e217-e228.	2.2	80
28	In situ analysis of C-C chemokine mRNA in human glomerulonephritis. <i>Kidney International</i> , 1998, 54, 827-836.	2.6	77
29	Calcineurin Inhibitor Sparing With Mycophenolate in Kidney Transplantation: A Systematic Review and Meta-Analysis. <i>Transplantation</i> , 2009, 87, 591-605.	0.5	75
30	The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action. <i>Kidney International</i> , 2021, 99, 791-793.	2.6	74
31	Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 2011-2013.	0.4	67
32	Serum Freeâ€œLight Chain Removal by High Cutoff Hemodialysis: Optimizing Removal and Supportive Care. <i>Artificial Organs</i> , 2008, 32, 910-917.	1.0	67
33	Current Trends of Renal Impairment in Multiple Myeloma. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 241-257.	1.2	66
34	Association of Caveolin-1 Gene Polymorphism With Kidney Transplant Fibrosis and Allograft Failure. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1282.	3.8	65
35	Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure. <i>Journal of the American Society of Nephrology: JASN</i> , 2012, 23, 1891-1899.	3.0	65
36	Symptom burden and health-related quality of life in chronic kidney disease: A global systematic review and meta-analysis. <i>PLoS Medicine</i> , 2022, 19, e1003954.	3.9	64

#	ARTICLE	IF	CITATIONS
37	Biological variation of measured and estimated glomerular filtration rate in patients with chronic kidney disease. <i>Kidney International</i> , 2019, 96, 429-435.	2.6	63
38	Association of Elevated Urinary miR-126, miR-155, and miR-29b with Diabetic Kidney Disease. <i>American Journal of Pathology</i> , 2018, 188, 1982-1992.	1.9	60
39	Serum free light chain assessment in monoclonal gammopathy and kidney disease. <i>Nature Reviews Nephrology</i> , 2009, 5, 621-628.	4.1	56
40	The Incidence of Major Hemorrhagic Complications After Renal Biopsies in Patients with Monoclonal Gammopathies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1977-1980.	2.2	56
41	Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease. <i>PLoS ONE</i> , 2017, 12, e0175200.	1.1	56
42	Renal TLR4 mRNA Expression Correlates with Inflammatory Marker MCP-1 and Profibrotic Molecule TGF- β 1 in Patients with Chronic Kidney Disease. <i>Nephron Clinical Practice</i> , 2011, 119, c97-c104.	2.3	54
43	Effect of Pamidronate on Bone Loss After Kidney Transplantation: A Randomized Trial. <i>American Journal of Kidney Diseases</i> , 2009, 53, 856-865.	2.1	52
44	Urinary endotrophin predicts disease progression in patients with chronic kidney disease. <i>Scientific Reports</i> , 2017, 7, 17328.	1.6	52
45	Chemoattraction of T cells expressing CCR5, CXCR3 and CX3CR1 by proximal tubular epithelial cell chemokines. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 734-744.	0.4	50
46	ABO-incompatible live donor renal transplantation using blood group A/B carbohydrate antigen immunoadsorption and anti-CD20 antibody treatment. <i>Xenotransplantation</i> , 2006, 13, 148-153.	1.6	50
47	Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 261-269.	0.5	50
48	Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England. <i>PLoS ONE</i> , 2018, 13, e0207960.	1.1	45
49	A Quantitative Survey of Western Muslim Attitudes to Solid Organ Donation. <i>Transplantation</i> , 2011, 92, 1108-1114.	0.5	43
50	Development and Evaluation of a Composite Risk Score to Predict Kidney Transplant Failure. <i>American Journal of Kidney Diseases</i> , 2011, 57, 744-751.	2.1	43
51	Expression of renal 11 β -hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function. <i>European Journal of Endocrinology</i> , 2005, 153, 291-299.	1.9	41
52	Quantitative assessment of serum and urinary polyclonal free light chains in patients with type II diabetes: an early marker of diabetic kidney disease?. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 667-676.	1.5	41
53	CD248+ stromal cells are associated with progressive chronic kidney disease. <i>Kidney International</i> , 2011, 80, 199-207.	2.6	41
54	Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational Study. <i>PLoS ONE</i> , 2016, 11, e0165675.	1.1	41

#	ARTICLE	IF	CITATIONS
55	Comparison of the Predictive Performance of eGFR Formulae for Mortality and Graft Failure in Renal Transplant Recipients. <i>Transplantation</i> , 2009, 87, 384-392.	0.5	40
56	A patient-centred approach to measuring quality in kidney care. <i>Current Opinion in Nephrology and Hypertension</i> , 2017, 26, 442-449.	1.0	39
57	Novel approaches for reducing free light chains in patients with myeloma kidney. <i>Nature Reviews Nephrology</i> , 2012, 8, 234-243.	4.1	37
58	The natural history of, and risk factors for, progressive Chronic Kidney Disease (CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. <i>BMC Nephrology</i> , 2013, 14, 95.	0.8	37
59	Serum Polyclonal Immunoglobulin Free Light Chain Levels Predict Mortality in People With Chronic Kidney Disease. <i>Mayo Clinic Proceedings</i> , 2014, 89, 615-622.	1.4	37
60	Patient and Clinician Perspectives on Electronic Patient-Reported Outcome Measures in the Management of Advanced CKD: A Qualitative Study. <i>American Journal of Kidney Diseases</i> , 2019, 74, 167-178.	2.1	37
61	Incidence and impact on outcomes of acute kidney injury after a stroke: a systematic review and meta-analysis. <i>BMC Nephrology</i> , 2018, 19, 283.	0.8	36
62	Identification of the Optimal Donor Quality Scoring System and Measure of Early Renal Function in Kidney Transplantation. <i>Transplantation</i> , 2009, 87, 578-586.	0.5	35
63	Serum Free Light Chains and the Risk of ESRD and Death in CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2829-2837.	2.2	35
64	Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation. <i>Transplant International</i> , 2009, 22, 681-687.	0.8	34
65	Differential progression of renal scarring and determinants of late renal recovery in sustained dialysis dependent acute kidney injury secondary to myeloma kidney. <i>Journal of Clinical Pathology</i> , 2010, 63, 884-887.	1.0	34
66	The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease - prospective longitudinal study in a multiethnic population. <i>BMC Nephrology</i> , 2014, 15, 13.	0.8	34
67	Oxidative stress links periodontal inflammation and renal function. <i>Journal of Clinical Periodontology</i> , 2021, 48, 357-367.	2.3	34
68	A collaborative, individual-level analysis compared longitudinal outcomes across the International Network of Chronic Kidney Disease (iNETCKD) cohorts. <i>Kidney International</i> , 2019, 96, 1217-1233.	2.6	33
69	Resuming liver transplantation amid the COVID-19 pandemic. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 725-726.	3.7	33
70	Predicting early renal allograft function using clinical variables. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2669-2677.	0.4	32
71	Assessing and Comparing Rival Definitions of Delayed Renal Allograft Function for Predicting Subsequent Graft Failure. <i>Transplantation</i> , 2010, 90, 1113-1116.	0.5	31
72	The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease. <i>Kidney International</i> , 2015, 87, 692-697.	2.6	31

#	ARTICLE	IF	CITATIONS
73	Serum free light chain level at diagnosis in myeloma cast nephropathy—a multicentre study. <i>Blood Cancer Journal</i> , 2020, 10, 28.	2.8	31
74	Chronic Kidney Disease After Nonrenal Solid Organ Transplantation. <i>Transplantation</i> , 2012, 93, 406-411.	0.5	30
75	Management options for cast nephropathy in multiple myeloma. <i>Current Opinion in Nephrology and Hypertension</i> , 2010, 19, 550-555.	1.0	28
76	T Lymphocyte Adhesion Mechanisms within Inflamed Human Kidney. <i>American Journal of Pathology</i> , 1999, 154, 503-514.	1.9	27
77	The Impact of Hemoglobin Levels on Patient and Graft Survival in Renal Transplant Recipients. <i>Transplantation</i> , 2008, 86, 564-570.	0.5	27
78	Hepatitis C and Kidney Transplantation. <i>International Journal of Nephrology</i> , 2011, 2011, 1-17.	0.7	27
79	The Need for Improved Identification and Accurate Classification of Stages 3–5 Chronic Kidney Disease in Primary Care: Retrospective Cohort Study. <i>PLoS ONE</i> , 2014, 9, e100831.	1.1	26
80	Allopurinol Is an Independent Determinant of Improved Arterial Stiffness in Chronic Kidney Disease: A Cross-Sectional Study. <i>PLoS ONE</i> , 2014, 9, e91961.	1.1	26
81	Reflections on the national patient-reported outcome measures (PROMs) programme: Where do we go from here?. <i>Journal of the Royal Society of Medicine</i> , 2016, 109, 441-445.	1.1	25
82	Glucocorticoid activation by 11 β -hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study. <i>Clinical Endocrinology</i> , 2019, 90, 241-249.	1.2	25
83	The periodontal health component of the Renal Impairment In Secondary Care (RIISC) cohort study: a description of the rationale, methodology and initial baseline results. <i>Journal of Clinical Periodontology</i> , 2014, 41, 653-661.	2.3	24
84	Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. <i>BMC Nephrology</i> , 2018, 19, 178.	0.8	24
85	The evolving role of chemokines and their receptors in acute allograft rejection. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1374-1379.	0.4	23
86	Impact of Using Risk-Based Stratification on Referral of Patients With Chronic Kidney Disease From Primary Care to Specialist Care in the United Kingdom. <i>Kidney International Reports</i> , 2021, 6, 2189-2199.	0.4	23
87	Organ Trafficking for Live Donor Kidney Transplantation in Indoasians Resident in the West Midlands: High Activity and Poor Outcomes. <i>Transplantation</i> , 2010, 89, 1456-1461.	0.5	22
88	Using patient-reported outcome measures (PROMs) to promote quality of care in the management of patients with established kidney disease requiring treatment with haemodialysis in the UK (PROM-HD): a qualitative study protocol. <i>BMJ Open</i> , 2018, 8, e021532.	0.8	22
89	Development and usability testing of an electronic patient-reported outcome measure (ePROM) system for patients with advanced chronic kidney disease. <i>Computers in Biology and Medicine</i> , 2018, 101, 120-127.	3.9	22
90	Patients with multiple myeloma have excellent long-term outcomes after recovery from dialysis-dependent acute kidney injury. <i>European Journal of Haematology</i> , 2016, 96, 610-617.	1.1	21

#	ARTICLE	IF	CITATIONS
91	Resolution of cast nephropathy following free light chain removal by haemodialysis in a patient with multiple myeloma: a case report. <i>Journal of Medical Case Reports</i> , 2008, 2, 380.	0.4	20
92	Increased incidence of infections following the late introduction of mycophenolate mofetil in renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 4049-4053.	0.4	20
93	Optimising the accuracy of blood pressure monitoring in chronic kidney disease: the utility of BpTRU. <i>BMC Nephrology</i> , 2013, 14, 218.	0.8	20
94	Association of Serum Ig Free Light Chains with Mortality and ESRD among Patients with Nondialysis-Dependent CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 740-749.	2.2	20
95	Serum tryptase concentration and progression to end-stage renal disease. <i>European Journal of Clinical Investigation</i> , 2016, 46, 460-474.	1.7	20
96	A population-based study of the impact of dialysis on mortality in multiple myeloma. <i>British Journal of Haematology</i> , 2018, 180, 588-591.	1.2	20
97	Distribution of plasma oxidised phosphatidylcholines in chronic kidney disease and periodontitis as a co-morbidity. <i>Free Radical Biology and Medicine</i> , 2020, 146, 130-138.	1.3	20
98	Kidney injury and disease in patients with haematological malignancies. <i>Nature Reviews Nephrology</i> , 2021, 17, 386-401.	4.1	20
99	KIR and HLA-C Interactions Promote Differential Dendritic Cell Maturation and Is a Major Determinant of Graft Failure following Kidney Transplantation. <i>PLoS ONE</i> , 2011, 6, e23631.	1.1	20
100	Henoch-Schönlein nephritis and non-Hodgkin's lymphoma. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1080-1081.	0.4	18
101	Imbalanced turnover of collagen type III is associated with disease progression and mortality in high-risk chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 593-601.	1.4	18
102	Does immunosuppressant medication lower blood pressure and arterial stiffness in patients with chronic kidney disease? An observational study. <i>Hypertension Research</i> , 2011, 34, 113-119.	1.5	17
103	The Use of Patient-Reported Outcomes in Patients Treated With Maintenance Hemodialysis: A Perspective. <i>American Journal of Kidney Diseases</i> , 2019, 74, 399-406.	2.1	17
104	The impact of chronic kidney disease and cardiovascular comorbidity on mortality in a multiethnic population: a retrospective cohort study. <i>BMJ Open</i> , 2013, 3, e003458.	0.8	16
105	Using Patient-Reported Outcome Measures (PROMs) to promote quality of care and safety in the management of patients with Advanced Chronic Kidney disease (PRO-track project): a mixed-methods project protocol. <i>BMJ Open</i> , 2017, 7, e016687.	0.8	16
106	Development of an electronic patient-reported outcome measure (ePROM) system to aid the management of patients with advanced chronic kidney disease. <i>Journal of Patient-Reported Outcomes</i> , 2020, 4, 55.	0.9	16
107	Survival and transplantation in end-stage renal disease: a prospective study of a multiethnic population. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3840-3846.	0.4	15
108	Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1438-1438.	0.4	15

#	ARTICLE	IF	CITATIONS
109	Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy. BMC Clinical Pathology, 2012, 12, 12.	1.8	15
110	A novel biomarker of laminin turnover is associated with disease progression and mortality in chronic kidney disease. PLoS ONE, 2018, 13, e0204239.	1.1	15
111	Measuring Renal Function in Solid Organ Transplant Recipients. Transplantation, 2007, 83, 529-531.	0.5	14
112	Recent Advances in the Pathogenesis and Management of Cast Nephropathy (Myeloma Kidney). Bone Marrow Research, 2011, 2011, 1-9.	1.7	14
113	An overview of the diagnosis and management of immunoglobulin G-related disease. Cmaj, 2016, 188, 953-961.	0.9	14
114	Role of Leukocytes in the Immunopathogenesis of ANCA-Associated Glomerulonephritis. Nephron, 2000, 85, 287-306.	0.9	13
115	Methods Used in Economic Evaluations of Chronic Kidney Disease Testing – A Systematic Review. PLoS ONE, 2015, 10, e0140063.	1.1	13
116	Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B. BMJ Case Reports, 2020, 13, e233072.	0.2	13
117	Risk factors for acute rejection in renal transplant recipients experiencing delayed graft function. Clinical Transplantation, 2008, 22, 634-638.	0.8	12
118	Rhabdomyolysis and Acute Kidney Injury. New England Journal of Medicine, 2009, 361, 1411-1413.	13.9	12
119	T Lymphocyte Responses to Nonpolymorphic HLA-Derived Peptides Are Associated With Chronic Renal Allograft Dysfunction. Transplantation, 2011, 91, 279-286.	0.5	12
120	The Association of Serum Free Light Chains With Mortality and Progression to End-Stage Renal Disease in Chronic Kidney Disease: Systematic Review and Individual Patient Data Meta-analysis. Mayo Clinic Proceedings, 2017, 92, 1671-1681.	1.4	12
121	The Association between Polyclonal Combined Serum Free Light Chain Concentration and Mortality in Individuals with Early Chronic Kidney Disease. PLoS ONE, 2015, 10, e0129980.	1.1	12
122	Caveolin-1 single-nucleotide polymorphism and arterial stiffness in non-dialysis chronic kidney disease. Nephrology Dialysis Transplantation, 2016, 31, 1140-1144.	0.4	10
123	Increased fracture risk in plasma cell dyscrasias is associated with poorer overall survival. British Journal of Haematology, 2017, 179, 61-65.	1.2	10
124	Measurement properties of patient-reported outcome measures (PROMs) used in adult patients with chronic kidney disease: a systematic review protocol. BMJ Open, 2016, 6, e012014.	0.8	8
125	Arterial stiffness alone does not explain arteriovenous fistula outcomes. Journal of Vascular Access, 2018, 19, 63-68.	0.5	8
126	Calciphylaxis following kidney transplantation: a case report. Journal of Medical Case Reports, 2009, 3, 9297.	0.4	7

#	ARTICLE	IF	CITATIONS
127	The Rationale and Evidence Base for the Direct Removal of Serum-Free Light Chains in the Management of Myeloma Kidney. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 324-332.	0.6	7
128	Renal transplantation in adults. <i>BMJ</i> , 2016, 355, i6158.	3.0	7
129	Influence of Successful Periodontal Intervention in REnal Disease (INSPIRED): study protocol for a randomised controlled pilot clinical trial. <i>Trials</i> , 2017, 18, 535.	0.7	7
130	Cross-sectional observation study to investigate the impact of risk-based stratification on care pathways for patients with chronic kidney disease: protocol paper. <i>BMJ Open</i> , 2019, 9, e027315.	0.8	7
131	Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. <i>Blood Advances</i> , 2020, 4, 5836-5845.	2.5	7
132	Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease. <i>PLoS ONE</i> , 2018, 13, e0197043.	1.1	6
133	Acute kidney injury calculated using admission serum creatinine underestimates 30-day and 1-year mortality after acute stroke. <i>CKJ: Clinical Kidney Journal</i> , 2020, 13, 46-54.	1.4	6
134	Quantification of polyclonal free light chains in clinical samples using a single turbidimetric immunoassay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2014, 52, 1605-13.	1.4	5
135	Achieving an Early Myeloma Response in Patients With Kidney Impairment. <i>Advances in Chronic Kidney Disease</i> , 2012, 19, 303-311.	0.6	4
136	Humoral immunity to memory antigens and pathogens is maintained in patients with chronic kidney disease. <i>PLoS ONE</i> , 2018, 13, e0195730.	1.1	4
137	Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study. <i>PLoS Medicine</i> , 2020, 17, e1003050.	3.9	4
138	Results of a pilot feasibility randomised controlled trial exploring the use of an electronic patient-reported outcome measure in the management of UK patients with advanced chronic kidney disease. <i>BMJ Open</i> , 2022, 12, e050610.	0.8	4
139	Islet cell transplantation. <i>Journal of the Royal Society of Medicine</i> , 2002, 95, 31-33.	1.1	2
140	Successful Renal Outcome in Membranoproliferative Glomerulonephritis Following Treatment of the Underlying Subtle Clone: A Case Report. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2018, 2, 297-302.	1.2	1
141	COVID-19 guidance in chronic diseases: a need to reach across the borders of the traditional medical specialities. <i>Frontline Gastroenterology</i> , 2020, 11, 332-333.	0.9	1
142	Impacts of the COVID-19 pandemic on training, morale and wellbeing among the UK renal workforce. <i>Clinical Medicine</i> , 2021, 21, 62-63.	0.8	1
143	Multiple Myeloma and the Kidney. , 2014, , 303-310.		1
144	Free light chains in plasma cell disorders: measurement and therapeutic implications. <i>Dialysis Y Trasplante</i> , 2009, 30, 21-23.	0.4	0

#	ARTICLE	IF	CITATIONS
145	Post-transplant Monoclonal Gammopathy of Renal Significance: A Case Series. Transplantation Proceedings, 2020, 52, 857-864.	0.3	0
146	The authors reply. Kidney International, 2020, 97, 214-215.	2.6	0
147	High Cut Off Hemodialysis. , 2016, , 257-268.		0
148	Successful virtual UK Kidney Week sees record-breaking registration. Journal of Kidney Care, 2020, 5, 290-291.	0.1	0